In episode 6 of Moving Medicine Forward, we dive into diversity in clinical research with insights from CTI’s CEO Tim Schroeder and Board Member Dr. Bill Fitzsimmons. Hear about Bill's journey into clinical research, the importance of diversity in clinical trials, and strategies to overcome medical mistrust. We also discuss the latest FDA guidance on diversity* and CTI’s initiatives to foster inclusive practices.

0:29 - Introduction of guests, Tim Schroeder, CEO of CTI, and Bill Fitzsimmons, CTI Board Member.

2:20 - Bill shares his journey into clinical research and how he became involved with CTI.

2:45 - Bill's role and responsibilities as a CTI board member.

3:36 - Defining diversity in clinical research.

4:10 - The importance of diversity in clinical trials.

7:15 - Strategies to encourage participation in clinical trials despite medical mistrust.

12:54 - Reference to Adam Roth’s episode on vaccine trials during COVID-19: Clinical Research Site Spotlight - Vaccine Trials by Moving Medicine Forward (spotify.com)

13:00 - Challenges in maintaining diversity within clinical trials.

14:52 - Impact of regulations and strict requirements for diverse populations on the clinical trial process.

*15:15 - The FDA guidance on diversity in clinical trials mentioned during the episode has since been published. Please note that the episode was recorded prior to its release.

19:23 - Essential support needed for clinical trial sites to successfully recruit diverse populations.

20:57 - Role of CROs in supporting sites to recruit diverse populations.

23:38 - Improving health and research literacy to enhance participation.

28:56 - CTI’s initiatives to enhance diversity in clinical research.